A Randomized Controlled Clinical Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor in Chemotherapy-induced Neutropenia
Shiyong ZHOU,Huaqing WANG,Huilai ZHANG,Lihua QIU,Zhengzi QIAN,Wei LI,Yun HOU,Kai FU,Xianming LIU,Xiuzhen CUI
DOI: https://doi.org/10.3969/j.issn.1000-8179.2011.18.025
2011-01-01
Chinese Journal of Clinical Oncology
Abstract:Objective:To compare the efficacy and safety of a single subcutaneous injection of PEG-rhG-CSF and daily rhG-CSF in chemotherapy-induced neutropenia.Methods:In the present randomized,open-label,match,and cross-over study,78 patients with previously untreated non-small cell lung cancer,breast cancer,and non-Hodgkin's lymphoma with normal bone marrow function were enrolled.The patients were randomized into AB and BA groups.Each patient received two cycles of chemotherapy with identical regimens. In the study cycle,they received a single subcutaneous injection of 100μg/kg PEG-rhG-CSF on day 3;and in the control cycle, daily subcutaneous infections of 5μg/kg/d rhG-CSF began on day 3 and continued either for 14 days or until the absolute neutrophil count(ANC)>5.0×10~9/L twice post nadir,whichever occurred first.The efficacy and safety parameters were monitored.Results: The incidence of ANC<1.5×10~9/L in 76 evaluable study cycles and 74 evaluable control cycles were 30.00%and 21.00%,with durations of 2.34 days and 2.31 days,respectively.Additionally,those with grade 4 neutropenia were 3.80%and 3.00%,respectively,in the trial and control cycles.The differences above were not statistically significant.None of the patients experienced febrile neutropenia after receiving PEG-rhG-CSF and rhG-CSF.Compared with that of rhG-CSF,the ANC profile of PEG-rhG-CSF exhibited limited"overshoot"of neutrophils after the nadir.Subgroup analysis according to disease type yielded similar results.The safety profiles of PEG-rhG-CSF and rhG-CSF were similar.Musculoskeletal pain or arthralgias occurred in 16.5%of the cases during the study cycles and 26.00%in the control cycles(P=0.963),which were mostly mild or moderate.Other adverse effects,such as fever,fatigue,dizziness, gastrointestinal effects and injection-site pain,were transient and easily manageable.Conclusion:A single subcutaneous injection of 100μg/kg PEG-rhG-CSF provides neutrophil support and a safety profile comparable to daily subcutaneous injections of 5μg/kg/d rhG-CSF in Chinese patients receiving a variety of myelosuppressive chemotherapy regimens.